Corbus Pharmaceuticals Files 8-K on Shareholder Vote & Other Events

Ticker: CRBP · Form: 8-K · Filed: May 19, 2025 · CIK: 1595097

Sentiment: neutral

Topics: corporate-governance, shareholder-meeting, regulatory-filing

Related Tickers: CRBP

TL;DR

CRBP filed an 8-K for a shareholder vote and other events on 5/15.

AI Summary

Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders and other events that occurred on May 15, 2025. The filing does not contain specific details about the nature of the vote or the other events.

Why It Matters

This filing indicates that Corbus Pharmaceuticals held a shareholder vote and experienced other significant events on May 15, 2025, which could impact the company's governance or operations.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting routine events without disclosing specific financial or operational changes that would immediately impact risk.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Corbus Pharmaceuticals' security holders on May 15, 2025?

The filing does not specify the exact matters voted upon by security holders on May 15, 2025.

What were the 'Other Events' reported by Corbus Pharmaceuticals on May 15, 2025?

The filing does not provide details regarding the specific 'Other Events' that occurred on May 15, 2025.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on May 19, 2025.

What is Corbus Pharmaceuticals Holdings, Inc.'s principal executive office address?

Corbus Pharmaceuticals Holdings, Inc.'s principal executive office is located at 500 River Ridge Drive, Norwood, Massachusetts 02062.

What is the Commission File Number for Corbus Pharmaceuticals Holdings, Inc.?

The Commission File Number for Corbus Pharmaceuticals Holdings, Inc. is 001-37348.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Corbus Pharmaceuticals Holdings, Inc. (CRBP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing